Dianthus Therapeutics, Inc.
- Open
- 96.68
- Day high
- 97.55
- Day low
- 90.37
- Prev close
- 97.48
- Volume
- 397K
- Mkt cap
- $5.0B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 4.1
- P/S
- 3726.2
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$5.6M over the last 3 months (0 open-market buys, 7 sales)
- 🏛Institutions accumulating (13F)
Dianthus Therapeutics, Inc. (DNTH) is a Healthcare company listed on NASDAQ. The stock is up 443% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 7 sales (SEC Form 4).
Dianthus Therapeutics, Inc. (DNTH) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
DNTH earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 5, 2026 | $-1.17 | $-0.85 | +27.4% | $463000 | +14.7% |
| Mar 9, 2026 | $-1.01 | $-1.43 | -42.2% | $284000 | +17.2% |
| Nov 5, 2025 | $-0.86 | $-0.97 | -12.8% | $396000 | -0.5% |
| Aug 7, 2025 | $-0.86 | $-0.88 | -2.3% | $193000 | -77.7% |
| Mar 11, 2025 | $-0.85 | $-0.81 | +4.7% | $1M | +38.8% |
| Nov 7, 2024 | $-0.59 | $-0.74 | -25.4% | $2M | +157.3% |
| Aug 8, 2024 | $-0.50 | $-0.51 | -2.0% | $2M | +482.2% |
| May 9, 2024 | $-0.43 | $-0.54 | -25.6% | $874000 | +90.0% |
| Mar 21, 2024 | $-1.11 | $-0.71 | +36.0% | $457000 | +47.4% |
| Nov 9, 2023 | $-0.51 | $-3.78 | -641.2% | $924000 | +125.4% |
| Aug 3, 2023 | $-0.19 | $-0.05 | +73.7% | $969000 | — |
| Sep 29, 2022 | $-4.64 | $-2.10 | +54.7% | $1M | — |
DNTH insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 18, 2026 | Veness Adam Mofficer: SVP, General Counsel and Sec. | Sell | 13,229 | $81.38 |
| Jun 18, 2026 | Veness Adam Mofficer: SVP, General Counsel and Sec. | Option | 30,000 | $17.88 |
| Jun 18, 2026 | Veness Adam Mofficer: SVP, General Counsel and Sec. | Sell | 16,771 | $80.34 |
| Jun 2, 2026 | Randhawa Simratofficer: EVP, Head of R&D | Sell | 4,159 | $91.37 |
| Jun 2, 2026 | Randhawa Simratofficer: EVP, Head of R&D | Option | 3,998 | $8.44 |
| Jun 2, 2026 | Randhawa Simratofficer: EVP, Head of R&D | Option | 6,908 | $17.88 |
| Jun 2, 2026 | Randhawa Simratofficer: EVP, Head of R&D | Option | 6,249 | $21.77 |
| Jun 2, 2026 | Randhawa Simratofficer: EVP, Head of R&D | Option | 9,375 | $22.07 |
| Jun 2, 2026 | Randhawa Simratofficer: EVP, Head of R&D | Sell | 5,428 | $89.72 |
| Jun 2, 2026 | Randhawa Simratofficer: EVP, Head of R&D | Sell | 16,943 | $90.72 |
| May 22, 2026 | Soteropoulos Pauladirector | Grant | 6,090 | $89.63 |
| May 22, 2026 | Violin Jonathandirector | Grant | 6,090 | $89.63 |
| May 22, 2026 | Romano Steven J.director | Grant | 6,090 | $89.63 |
| May 22, 2026 | Read Simondirector | Grant | 6,090 | $89.63 |
| May 22, 2026 | Lawton Alison Francesdirector | Grant | 6,090 | $89.63 |
Source: DNTH SEC Form 4 filings, latest Jun 18, 2026. For informational purposes only — not investment advice.
See the full DNTH insider & 13F page →Dianthus Therapeutics, Inc. company profile
Overview
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is a clinical-stage biotechnology company founded in 2015 and headquartered in New York, New York. The company went public in June 2018 and focuses on developing novel monoclonal antibody treatments for patients suffering from severe autoimmune and inflammatory diseases. Dianthus is currently advancing its lead drug candidate, DNTH103, through Phase 1 clinical trials for multiple neurological conditions including generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Business
Dianthus Therapeutics operates in the biotechnology sector, specifically focusing on developing treatments for autoimmune and inflammatory diseases that affect the nervous system. The company's core expertise lies in designing and developing monoclonal antibodies, which are laboratory-created proteins that can bind to specific targets in the body to treat disease. The company's primary focus is on neurological autoimmune conditions, which are diseases where the body's immune system mistakenly attacks its own nervous system components. Their lead product candidate is DNTH103, a monoclonal antibody currently in Phase 1 clinical trials. This drug is being tested for three specific conditions: 1. Generalized Myasthenia Gravis - A chronic autoimmune disorder that causes muscle weakness and fatigue by disrupting communication between nerves and muscles. Patients experience difficulty with eye movements, facial expressions, chewing, talking, and swallowing. 2. Multifocal Motor Neuropathy - A rare neurological disorder that causes progressive weakness in specific muscle groups, typically starting in the hands and arms, without affecting sensation. 3. Chronic Inflammatory Demyelinating Polyneuropathy - A neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms, caused by damage to the protective covering of nerves. These conditions represent significant unmet medical needs, as current treatment options are often limited, have significant side effects, or lose effectiveness over time. The biotechnology industry focuses on developing innovative treatments through extensive research and clinical testing, which can take many years and require substantial investment before generating revenue.
Revenue model
As a clinical-stage biotechnology company, Dianthus Therapeutics does not yet generate revenue from product sales. The company's current revenue of approximately $1-2 million per quarter comes primarily from collaboration agreements and licensing deals with other pharmaceutical companies or research institutions. This is typical for early-stage biotech companies that are still developing their products. The company's future business model will be based on product sales and licensing once DNTH103 receives regulatory approval. Biotechnology companies typically make money through several mechanisms: direct sales of approved drugs to hospitals and healthcare providers, licensing agreements with larger pharmaceutical companies for manufacturing and distribution rights, and royalty payments from partners who commercialize their products in different geographic markets. The paying customers for Dianthus's future products will primarily be healthcare systems, hospitals, and specialty clinics that treat patients with autoimmune neurological conditions. Given the specialized nature of these diseases, the company will likely work with neurologists and other specialists who have expertise in treating these rare conditions. Several factors could significantly impact Dianthus's future profitability. Regulatory approval success is the most critical factor - failure to demonstrate safety and efficacy in clinical trials would eliminate revenue potential entirely. Competition from other treatments, including both existing therapies and new drugs in development by larger pharmaceutical companies, could limit market share and pricing power. Healthcare reimbursement policies will also be crucial, as insurance coverage decisions directly affect patient access and company revenues. Additionally, manufacturing costs and scale will impact margins, as biologics like monoclonal antibodies are expensive to produce and require specialized facilities. The company's ability to secure partnerships with larger pharmaceutical companies could provide additional revenue streams and reduce commercialization risks.
Competitive moat
Dianthus Therapeutics currently operates with a relatively narrow competitive moat, which is typical for early-stage biotechnology companies. The company's primary competitive advantages stem from its intellectual property portfolio around DNTH103 and its specific approach to targeting autoimmune neurological conditions. Patents provide temporary protection, but these typically expire 20 years from filing, and competitors can often develop alternative approaches to target the same diseases. The company's focus on rare neurological autoimmune diseases provides some natural protection due to the specialized expertise required and smaller market sizes that may not attract large pharmaceutical companies initially. However, this also limits the total addressable market and revenue potential. The main competitive threats come from several sources. Large pharmaceutical companies with significantly more resources could develop competing treatments more quickly and with greater financial backing. Academic research institutions and other biotechnology companies are also working on treatments for similar conditions, potentially with different mechanisms of action that could prove more effective. Additionally, existing treatments for these conditions, while limited, still provide alternatives for patients and physicians. The company's moat could strengthen significantly if DNTH103 demonstrates superior efficacy and safety compared to existing treatments in clinical trials. Success in Phase 1 trials and advancement to later-stage studies would provide more competitive protection, as would any additional patents or regulatory advantages such as orphan drug designation for rare diseases. However, until the company has proven clinical results and regulatory approval, its competitive position remains vulnerable to better-funded competitors and alternative treatment approaches.
Risks & safety
Dianthus Therapeutics presents a moderate margin of safety from a financial solvency perspective, though significant execution risks remain as a clinical-stage biotech company. • Cash Position: The company maintains approximately $10-23 million in cash and short-term investments as of Q1 2025, down from over $300 million in Q2 2024, indicating significant cash burn. • Burn Rate: Operating cash flow burn of approximately $27-28 million per quarter suggests the current cash position provides less than one year of runway at current spending levels. • Debt Level: Minimal debt with debt-to-equity ratio of 0.004, indicating very low financial leverage and solvency risk. • Current Ratio: Strong liquidity position with current ratio of 16.0, meaning current assets significantly exceed current liabilities. • Valuation Metrics: Trading at negative P/E ratios due to losses, with price-to-book ratio of approximately 2.0, suggesting modest premium to book value. • Other Considerations: The company will likely need additional funding through equity raises or partnerships to continue operations beyond the near term, which could dilute existing shareholders. Clinical trial outcomes represent the primary risk to the investment thesis.
Recent development
Based on the available financial data, Dianthus Therapeutics has been primarily focused on advancing its lead compound DNTH103 through Phase 1 clinical trials over the past few years. The company has maintained a consistent focus on developing treatments for autoimmune neurological conditions, specifically generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. The most significant development pattern visible in the financial statements is the company's substantial increase in cash position in 2024, rising from approximately $15 million at the end of 2022 to over $300 million in Q2 2024, likely indicating a successful equity raise or partnership agreement to fund continued clinical development. However, this cash position has declined significantly by Q1 2025 to about $10 million, reflecting the high costs associated with clinical trial operations. Revenue has remained relatively modest, ranging from $1-2 million per quarter, suggesting the company continues to operate primarily as a research and development organization rather than generating significant commercial revenue. The consistency of this revenue stream indicates ongoing collaboration agreements or licensing arrangements that provide some funding support during the clinical development phase. The company's operating expenses have remained substantial, with quarterly losses of $25-30 million, reflecting the intensive resource requirements of conducting clinical trials for multiple indications simultaneously. This spending pattern is typical for biotechnology companies advancing multiple clinical programs and suggests active progression of their development timeline.
DNTH company profile · for informational purposes only — not investment advice.
Track DNTH with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free